

CITATION REPORT

List of articles citing

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

DOI: 10.2165/00003088-199732030-00004
Clinical Pharmacokinetics, 1997, 32, 210-58.

Source: <https://exaly.com/paper-pdf/28345950/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
567	Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients. <i>Clinical Pharmacokinetics</i> , 1997 , 33, 426-53	6.2	85
566	HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes. 1997 , 93, 215-9		44
565	Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. <i>Clinical Pharmacokinetics</i> , 1997 , 33, 454-71	6.2	129
564	In vitro analysis of the activity of the major human hepatic CYP enzyme (CYP3A4) using [N-methyl-14C]-erythromycin. 1997 , 38, 189-93		31
563	Geriatric clinical pharmacologist and medical oncologist: a new partnership?. 1997 , 62, 361-4		1
562	Effect of itraconazole on the pharmacokinetics of atorvastatin. 1998 , 64, 58-65		234
561	Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. 1998 , 63, 397-402		218
560	Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. 1998 , 64, 597-602		24
559	Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. 1998 , 64, 661-71		73
558	Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. 1998 , 64, 177-82		236
557	Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. 1998 , 63, 332-41		343
556	Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. 1998 , 64, 237-47		103
555	Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. 1998 , 64, 278-85		83
554	Novobiocin inhibits both UDP-glucuronosyltransferase and cytochrome P450-mediated enzyme activities in pig liver microsomes. 1998 , 22, 405-14		3
553	Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. 1998 , 87, 1184-9		53
552	Cytochrome P450, molecular biology and anaesthesia. 1998 , 42, 1025-7		6
551	3 The pharmacology of the cytochrome P450 enzyme system. 1998 , 12, 191-211		4

550	4 The role of the cytochrome P450 system in drug interactions in anaesthesia. 1998 , 12, 213-228		1
549	Human immunodeficiency virus therapy and potential anesthetic interactions. 1998 , 17, 299-307		4
548	Cassette dosing: rapid in vivo assessment of pharmacokinetics. 1998 , 1, 12-18		57
547	Psychotropic drug metabolism in the cancer patient: clinical aspects of management of potential drug interactions. 1998 , 7, 307-20		7
546	Le métabolisme comme source de variabilité de l'efficacité et de la toxicité des analgésiques. 1998 , 11, 77-82		3
545	Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. 1998 , 46, 49-53		143
544	Human CYP2D6 and metabolism of m-chlorophenylpiperazine. 1998 , 44, 1185-91		54
543	Drug-drug interactions in pediatric psychopharmacology. 1998 , 45, 1233-64, x-xi		11
542	In vitro and in vivo drug interactions involving human CYP3A. 1998 , 38, 389-430		709
541	Modulation of MDR1 and CYP3A expression by dexamethasone: evidence for an inverse regulation in adrenals. 1998 , 252, 392-5		46
540	Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. <i>Clinical Pharmacokinetics</i> , 1998 , 35, 275-91	6.2	339
539	Inhibition and induction of cytochrome P450 and the clinical implications. <i>Clinical Pharmacokinetics</i> , 1998 , 35, 361-90	6.2	585
538	A mechanistic approach to antiepileptic drug interactions. 1998 , 32, 554-63		201
537	Effects of propofol on human hepatic microsomal cytochrome P450 activities. <i>Xenobiotica</i> , 1998 , 28, 845-53	2	42
536	Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. 1998 , 38, 106-11		193
535	Fatal pharmacokinetic interaction involving amitriptyline combined with valproate and clozapine. 1998 , 15, 113-114		
534	Zidovudine azido-reductase in human liver microsomes: activation by ethacrynic acid, dipyridamole, and indomethacin and inhibition by human immunodeficiency virus protease inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 1998 , 42, 1654-8	5.9	20
533	Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients. 1999 , 39, 1085-93		7

532	Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. <i>Xenobiotica</i> , 1999 , 29, 217-29	2	43
531	Cytochrome P450 substrate specificities, substrate structural templates and enzyme active site geometries. 1999 , 15, 1-49		52
530	Significant interactions with new antiretrovirals and psychotropic drugs. 1999 , 33, 461-73		75
529	FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling. 1999 , 39, 899-910		56
528	Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. <i>Xenobiotica</i> , 1999 , 29, 53-75	2	135
527	Determination of testosterone and 6beta-hydroxytestosterone by gas chromatography-selected ion monitoring-mass spectrometry for the characterization of cytochrome p450 3A activity. 1999 , 734, 73-81		8
526	Automation of metabolic stability studies in microsomes, cytosol and plasma using a 215 Gilson liquid handler. 1999 , 19, 893-901		29
525	Functional significance of a C->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. 1999 , 47, 445-9		522
524	Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. 1999 , 48, 89-97		123
523	Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. 1999 , 40, 783-7		128
522	Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs. 1999 , 19, 491-510		31
521	Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zopiclone, and zolpidem. 1999 , 19, 533-52		48
520	Upper gastrointestinal tract bleeding in critically ill pediatric patients. 1999 , 19, 162-80		15
519	Impact of rifampin on serum amiodarone concentrations in a patient with congenital heart disease. 1999 , 19, 249-51		12
518	Absence of effect of stimulants on the pharmacokinetics of desipramine in children. 1999 , 19, 746-52		21
517	New insights into the pharmacodynamic and pharmacokinetic properties of statins. 1999 , 84, 413-28		592
516	Homology modeling and substrate binding study of human CYP2C18 and CYP2C19 enzymes. 1999 , 37, 204-17		12
515	Desipramine clearance in children and adolescents: absence of effect of development and gender. 1999 , 38, 79-85		13

514	Duplication, multiduplication, and amplification of genes encoding drug-metabolizing enzymes: evolutionary, toxicological, and clinical pharmacological aspects. 1999 , 31, 449-59		43
513	Psychotropic medications and HIV medicine: A rational approach. 1999 , 3, 229-36		1
512	Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. 1999 , 20, 342-9		411
511	Drug metabolism and atypical antipsychotics. 1999 , 9, 301-9		65
510	Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. 1999 , 46, 839-49		69
509	Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. <i>Clinical Pharmacokinetics</i> , 1999 , 36, 289-304	6.2	227
508	Effects of liver disease on pharmacokinetics. An update. <i>Clinical Pharmacokinetics</i> , 1999 , 37, 399-431	6.2	168
507	Wire and forget?N pharmacological considerations in coronary care. 1999 , 147 Suppl 1, S23-30		15
506	Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5Nupstream regulatory region. 1999 , 259, 201-5		262
505	Relationship between mRNA levels quantified by reverse transcription-competitive PCR and metabolic activity of CYP3A4 and CYP2E1 in human liver. 1999 , 262, 499-503		77
504	The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin. 1999 , 39, 86-90		24
503	The effect of erythromycin, fluvoxamine, and their combination on the pharmacokinetics of ropivacaine. 2000 , 91, 1207-12		7
502	A comparison of remifentanyl and alfentanil for use with propofol in patients undergoing minimally invasive coronary artery bypass surgery. 2000 , 90, 1269-74		14
501	CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations. 2000 , 10, 753-6		40
500	Drug interactions and donepezil. 2000 , 48, 597-8		3
499	Plasma concentrations of monoethylglycinexylidide during and after breast augmentation. 2000 , 106, 728-31		4
498	The Effect of Erythromycin, Fluvoxamine, and Their Combination on the Pharmacokinetics of Ropivacaine. 2000 , 91, 1207-1212		17
497	Differential impairment of triazolam and zolpidem clearance by ritonavir. 2000 , 24, 129-36		43

496	Effect of dietary oil intake on hepatic cytochrome P450 activity in the rat. 2000 , 89, 1022-7	15
495	Impact of mechanism-based enzyme inactivation on inhibitor potency: implications for rational drug discovery. 2000 , 89, 1404-14	28
494	Efavirenz therapy in drug users. 2000 , 1 Suppl 1, 15-7	8
493	In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. 2000 , 49, 343-51	75
492	Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin–ergotamine drug interaction. 2000 , 30, 635-6	5
491	ADME/PK as part of a rational approach to drug discovery. 2000 , 5, 409-414	174
490	Progress in predicting human ADME parameters in silico. 2000 , 44, 251-72	198
489	Psychotropic drugs and falls: new evidence pertaining to serotonin reuptake inhibitors. 2000 , 20, 308-17	28
488	Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. 2000 , 17, 336-43	95
487	Towards a new age of virtual ADME/TOX and multidimensional drug discovery. 2002 , 5, 255-75	20
486	Comparison of methods for analyzing kinetic data from mechanism-based enzyme inactivation: application to nitric oxide synthase. 2000 , 2, E8	32
485	Differential Impairment of Triazolam and Zolpidem Clearance by Ritonavir. 2000 , 24, 129-136	59
484	Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. 2000 , 1, 125-51	87
483	How to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transport. 2000 , 38, 869-76	27
482	Quantitative analysis of constitutive and inducible CYPs mRNA expression in the HepG2 cell line using reverse transcription-competitive PCR. 2000 , 267, 756-60	56
481	In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. 2000 , 47, 655-61	50
480	Multixenobiotic resistance as a cellular defense mechanism in aquatic organisms. 2000 , 48, 357-389	328
479	CYP2D6 gene polymorphism in caucasian smokers: lung cancer susceptibility and phenotype-genotype relationships. 2000 , 36, 1825-32	25

478	Galactorrhoea and hyperprolactinaemia associated with protease-inhibitors. 2000 , 356, 1003-4		41
477	Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection. 2000 , 2, E1		110
476	Carbamazepine--indinavir interaction causes antiretroviral therapy failure. 2000 , 34, 465-70		76
475	Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. 2000 , 32, 111-23		94
474	Trends in veterinary clinical and fundamental pharmacology: past and future in The Netherlands. 2000 , 22, 3-11		5
473	Use of everted sacs of mouse small intestine as enzyme sources for the study of drug oxidation activities in vitro. <i>Xenobiotica</i> , 2000 , 30, 971-82	2	22
472	Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. <i>Clinical Pharmacokinetics</i> , 2000 , 38, 111-80	6.2	396
471	Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants. <i>Clinical Pharmacokinetics</i> , 2000 , 38, 355-65	6.2	42
470	Biotransformation of post-clozapine antipsychotics: pharmacological implications. <i>Clinical Pharmacokinetics</i> , 2000 , 38, 393-414	6.2	58
469	Protracted Episode of Reduced Consciousness Following Co-Medication with Omeprazole and Clorazepate. 2000 , 19, 307-311		3
468	Automated high throughput human CYP isoform activity assay using SPE-LC/MS method: application in CYP inhibition evaluation. <i>Xenobiotica</i> , 2000 , 30, 141-54	2	67
467	Clinical-pharmacological strategies to assess drug interaction potential during drug development. 2001 , 24, 715-25		51
466	Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. <i>Clinical Pharmacokinetics</i> , 2001 , 40, 41-62	6.2	79
465	Clinical pharmacokinetics of fluvastatin. <i>Clinical Pharmacokinetics</i> , 2001 , 40, 263-81	6.2	116
464	Quantitative drug interactions prediction system (Q-DIPS): a dynamic computer-based method to assist in the choice of clinically relevant in vivo studies. <i>Clinical Pharmacokinetics</i> , 2001 , 40, 631-40	6.2	17
463	Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. 2001 , 281, 1349-55		149
462	Ergotism related to interaction between nelfinavir and ergotamine. 2001 , 110, 594		14
461	[Pharmacogenetics of cytochromes P450: practical implications]. 2001 , 8 Suppl 2, 350s-352s		

460	Pharmacogenomics: implications for laboratory medicine. 2001 , 308, 43-53		37
459	Benzodiazepines in the intensive care unit. 2001 , 17, 843-62		43
458	Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. 2001 , 41, 1043-54		50
457	Screening for detection of new antidepressants, neuroleptics, hypnotics, and their metabolites in urine by GC-MS developed using rat liver microsomes. <i>Therapeutic Drug Monitoring</i> , 2001 , 23, 61-70	3.2	63
456	Effect of low dose cyclosporine and sirolimus on hepatic drug metabolism in the rat1. 2001 , 71, 1585-92		13
455	Use of in vitro drug metabolism data to evaluate metabolic drug-drug interactions in man: the need for quantitative databases. 2001 , 41, 368-73		30
454	Preparation of the HIV-infected Traveler to the Tropics. 2001 , 3, 50-58		2
453	(Q) SAR study on the metabolic stability of steroidal androgens. 2001 , 19, 552-6, 607-8		18
452	CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. 2001 , 104, 173-92		285
451	Role of drug metabolism in drug discovery and development. 2001 , 21, 397-411		136
450	Enantioselective pharmacokinetics of the enantiomers of clevidipine following intravenous infusion of the racemate in essential hypertensive patients. 2001 , 13, 130-4		21
449	Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions. 2001 , 18, 622-31		44
448	Development of a generalized, quantitative physicochemical model of CYP3A4 inhibition for use in early drug discovery. 2001 , 18, 652-5		91
447	Drug metabolism and drug interactions in the elderly. 2001 , 15, 897-918		80
446	Problems associated with in vitro assessment of drug inhibition of CYP3A4 and other P-450 enzymes and its impact on drug discovery. 2001 , 45, 79-84		18
445	Pharmacotherapy of behavioral and psychological symptoms of dementia: time for a different paradigm?. 2001 , 21, 74-102		17
444	Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. <i>Antimicrobial Agents and Chemotherapy</i> , 2001 , 45, 382-92	5.9	141
443	Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. <i>Antimicrobial Agents and Chemotherapy</i> , 2001 , 45, 3445-50	5.9	117

442	Urinary excretion of diazepam metabolites in healthy volunteers and drug users. 2001 , 61, 237-46	13
441	Evaluation of the marmoset as a model species for drug glucuronidation. <i>Xenobiotica</i> , 2001 , 31, 849-60	24
440	Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. 2001 , 41, 1149-79	222
439	Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. 2001 , 41, 85-91	88
438	(+)-N-3-Benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19. 2002 , 30, 235-9	83
437	Effect of albumin and cytosol on enzyme kinetics of tolbutamide hydroxylation and on inhibition of CYP2C9 by gemfibrozil in human liver microsomes. 2002 , 302, 43-9	18
436	In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. 2002 , 301, 382-90	196
435	Interactions between recreational drugs and antiretroviral agents. 2002 , 36, 1598-613	97
434	5-HT(3)-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile. 2002 , 7, 424-36	84
433	The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials. 2002 , 35, 53-61	67
432	Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation. 2002 , 34, 751-90	17
431	Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administration. 2002 , 30, 1455-61	16
430	Sedation and analgesia in the intensive care unit. 2002 , 166, 1024-8	95
429	CYP3A4 gene polymorphisms influence testosterone 6beta-hydroxylation. <i>Drug Metabolism and Pharmacokinetics</i> , 2002 , 17, 150-6	2.2 45
428	The era of genomics: impact on sepsis clinical trial design. 2002 , 30, S341-8	34
427	Sedation in the intensive care unit. 2002 , 8, 290-8	65
426	Genetic polymorphism of the human cytochrome P450 CYP4B1: evidence for a non-functional allelic variant. 2002 , 12, 367-74	24
425	Microsomal enzyme induction and clinical aggravation of porphyria: the evaluation of human urinary 6beta-hydroxycortisol/cortisol ratio as the index of hepatic CYP3A4 activity. 2002 , 42, 1374-9	6

424	Effect of probucol on cytochrome P450 activities in human liver microsomes. 2002 , 25, 1112-4		9
423	Cytochrome P450 (CYP) expression in human myeloblastic and lymphoid cell lines. 2002 , 25, 383-5		60
422	Inhibition of human drug metabolizing cytochrome P450 by buprenorphine. 2002 , 25, 682-5		34
421	CYPalleles: a web page for nomenclature of human cytochrome P450 alleles. <i>Drug Metabolism and Pharmacokinetics</i> , 2002 , 17, 491-5	2.2	14
420	Human CYP allele database: submission criteria procedures and objectives. 2002 , 357, 28-36		5
419	Reversible coma caused by risperidone-ritonavir interaction. 2002 , 25, 251-3		30
418	Clinically significant interactions with drugs used in the treatment of tuberculosis. 2002 , 25, 111-33		68
417	Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. <i>Clinical Pharmacokinetics</i> , 2002 , 41, 343-70	6.2	305
416	Ontogeny of hepatic and renal systemic clearance pathways in infants: part II. <i>Clinical Pharmacokinetics</i> , 2002 , 41, 1077-94	6.2	121
415	Interactions between antiepileptic drugs and hormonal contraception. 2002 , 16, 263-72		119
414	Cytochrome p450 genotyping by multiplexed real-time dna sequencing with pyrosequencing technology. 2002 , 1, 49-59		44
413	Toxicidad hepática por fármacos. Dónde estamos y hacia dónde caminamos. 2002 , 56, 434-442		7
412	Management of protease inhibitor-associated hyperlipidemia. 2002 , 2, 91-106		31
411	Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. 2002 , 71, 1579-89		178
410	Pharmacological interactions of statins. 2002 , 3, 35-40		58
409	Drug interactions: Proteins, pumps, and P-450s. 2002 , 47, 467-84; quiz 485-8		74
408	Metabolism of tricyclic anticonvulsant drugs. 2002 , 3, S2-S6		13
407	Interacciones farmacocinéticas de los antimicrobianos. 2002 , 8, 3821-3830		

406	Interaction between grapefruit juice and praziquantel in humans. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 1614-6	5.9	47
405	Identification of catalase in human livers as a factor that enhances phenytoin dihydroxy metabolite formation by human liver microsomes. 2002 , 63, 2081-90		7
404	Cytochromes P450 and experimental models of drug metabolism. 2002 , 6, 189-98		217
403	Factors confounding the successful extrapolation of in vitro CYP3A inhibition information to the in vivo condition. 2002 , 15, 239-42		12
402	Inhibition-based metabolic drug-drug interactions: predictions from in vitro data. 2002 , 91, 1923-35		55
401	Effect of zolpidem on human cytochrome P450 activity, and on transport mediated by P-glycoprotein. 2002 , 23, 361-7		25
400	In vitro tests for predicting drug-drug interactions: the need for validated procedures. 2002 , 91, 209-17		27
399	In vitro effects of tacrolimus on human cytochrome P450. 2002 , 16, 455-60		15
398	Polymorphism of cytochrome P450 and xenobiotic toxicity. 2002 , 181-182, 447-52		77
397	Quantitative structure activity relationships for the glucuronidation of simple phenols by expressed human UGT1A6 and UGT1A9. 2002 , 30, 734-8		48
396	Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. 2002 , 19, 147-53		92
395	Towards a new age of virtual ADME/TOX and multidimensional drug discovery. 2002 , 16, 381-401		69
394	Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?. 2002 , 4, E25		64
393	Hepatic drug metabolism and transport in patients with kidney disease. 2003 , 42, 906-25		89
392	Characterization of bropridine O-glucuronidation in human liver microsomes. <i>Xenobiotica</i> , 2003 , 33, 999-1011	2	11
391	Effect of ciprofloxacin on the pharmacokinetics of ropivacaine. 2003 , 58, 653-7		18
390	Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study. 2003 , 59, 57-64		28
389	The effect of erythromycin on the pharmacokinetics of rosuvastatin. 2003 , 59, 51-6		63

388	Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man. 2003 , 59, 23-8		22
387	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. 2003 , 59, 429-42		191
386	Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. 2003 , 65, 109-20		12
385	Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. 2003 , 65, 1853-65		5
384	Increased transcriptional activity of the CYP3A4*1B promoter variant. 2003 , 42, 299-305		146
383	High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry. 2003 , 30, 1459-67		102
382	Demethylation of radiolabelled dextromethorphan in rat microsomes and intact hepatocytes. 2003 , 270, 3768-77		20
381	A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology. 2003 , 55, 175-81		45
380	Interaction of ibuprofen and probenecid with drug metabolizing enzyme phenotyping procedures using caffeine as the probe drug. 2003 , 55, 191-8		10
379	Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. 2003 , 55, 68-76		134
378	Genotyping of four genetic polymorphisms in the CYP1A2 gene in the Egyptian population. 2003 , 55, 321-4		35
377	Interactions of herbs with cytochrome P450. 2003 , 35, 35-98		320
376	Pyrosequencing AB. 2003 , 4, 217-21		2
375	Benefits and risks of newer treatments for chemotherapy-induced and postoperative nausea and vomiting. 2003 , 26, 227-59		31
374	Drug interactions between antiretroviral drugs and comedicated agents. <i>Clinical Pharmacokinetics</i> , 2003 , 42, 223-82	6.2	106
373	Factors affecting the clinical development of cytochrome p450 3A substrates. <i>Clinical Pharmacokinetics</i> , 2003 , 42, 969-84	6.2	44
372	Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. 2003 , 31, 289-93		245
371	In vitro metabolism of clindamycin in human liver and intestinal microsomes. 2003 , 31, 878-87		76

370	Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities. <i>Journal of Medicinal Chemistry</i> , 2003 , 46, 74-86	8.3	104
369	Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. 2003 , 409, 32-44		45
368	Cloning, tissue distribution, and functional studies of a new cytochrome P450 3A subfamily member, CYP3A45, from rainbow trout (<i>Oncorhynchus mykiss</i>) intestinal ceca. 2003 , 412, 77-89		25
367	A pilot study of plasma caffeine concentrations in a US sample of smoker and nonsmoker volunteers. 2003 , 27, 165-71		62
366	Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report. 2003 , 27, 1059-63		73
365	The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. 2003 , 1619, 243-53		255
364	An HIV-positive patient with epilepsy. 2003 , 4 Suppl 1, S17-9		1
363	Pharmacogenetics of drug metabolising enzymes: importance for personalised medicine. 2003 , 41, 573-80		50
362	The effect of incubation conditions on the enzyme kinetics of udp-glucuronosyltransferases. 2003 , 31, 762-7		139
361	Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era. 2003 , 2, 269-86		15
360	Induction of hepatic cytochrome P450s responsible for the metabolism of xenobiotics by nicardipine and other calcium channel antagonists in the male rat. <i>Xenobiotica</i> , 2003 , 33, 119-29	2	8
359	Inflammation increases sufentanil requirements during surgery for inflammatory bowel diseases. 2003 , 20, 957-962		3
358	Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. 2003 , 43, 414-22		45
357	Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine. <i>Journal of Clinical Psychopharmacology</i> , 2003 , 23, 349-57	1.7	16
356	Dose-related pharmacokinetics and pharmacodynamics of valproate in the elderly. <i>Journal of Clinical Psychopharmacology</i> , 2003 , 23, 471-8	1.7	15
355	Evaluation of methods for predicting drug-drug interactions by Monte Carlo simulation. <i>Drug Metabolism and Pharmacokinetics</i> , 2003 , 18, 121-7	2.2	21
354	[Drug interactions with antilipemics]. 2003 , 58, 85-90		6
353	Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. 2003 , 26, 510-7		56

352	Inflammation increases sufentanil requirements during surgery for inflammatory bowel diseases. 2003 , 20, 957-62		2
351	Incorporating children's toxicokinetics into a risk framework. 2004 , 112, 272-83		55
350	A pharmacokinetic interaction study between omeprazole and the H ₂ -receptor antagonist ranitidine. 2004 , 20, 273-81		3
349	Principles of pharmacogenetics--implications for the anaesthetist. 2004 , 93, 440-50		28
348	Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. 2004 , 32, 1247-53		241
347	Quantitative prediction of the in vivo inhibition of diazepam metabolism by omeprazole using rat liver microsomes and hepatocytes. 2004 , 32, 572-80		21
346	An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates. 2004 , 32, 715-21		59
345	An assessment of udp-glucuronosyltransferase induction using primary human hepatocytes. 2004 , 32, 140-8		125
344	Understanding the mechanisms of drug-associated interstitial lung disease. 2004 , 91 Suppl 2, S31-7		58
343	CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement. <i>Xenobiotica</i> , 2004 , 34, 875-87	2	14
342	Induction of hepatic cyp2b and cyp3a subfamily enzymes by nicardipine and nifedipine in mice. <i>Xenobiotica</i> , 2004 , 34, 607-18	2	6
341	Functional characterization of single nucleotide polymorphisms with amino acid substitution in CYP1A2, CYP2A6, and CYP2B6 found in the Japanese population. <i>Drug Metabolism and Pharmacokinetics</i> , 2004 , 19, 444-52	2.2	9
340	Identification of the novel canine CYP1A2 1117 C > T SNP causing protein deletion. <i>Xenobiotica</i> , 2004 , 34, 835-46	2	35
339	The influence of statin characteristics on their safety and tolerability. 2004 , 58, 945-55		31
338	Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. 2004 , 57, 473-86		239
337	Pharmacogenomics in cardiovascular clinical trials. 2004 , 18, 705-8		1
336	Sex difference in induction of hepatic CYP2B and CYP3A subfamily enzymes by nicardipine and nifedipine in rats. 2004 , 196, 20-8		14
335	Factors influencing the choice of 5-HT ₃ -receptor antagonist antiemetics: focus on elderly cancer patients. 2004 , 12, 487-96		7

334	Genetic polymorphisms and prostate cancer risk. 2004 , 21, 414-23		45
333	Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. 2004 , 369, 89-104		235
332	A topological sub-structural approach for predicting human intestinal absorption of drugs. <i>European Journal of Medicinal Chemistry</i> , 2004 , 39, 905-16	6.8	55
331	Pharmacokinetic interactions of drugs with St John's wort. 2004 , 18, 262-76		195
330	Delirium and sedation. 2004 , 20, 419-33, ix		14
329	Drug Metabolism In Preclinical Development. 2004 , 75-132		1
328	Detection of clinical interactions between methadone and anti-retroviral compounds using an enantioselective capillary electrophoresis for methadone analysis. 2004 , 151, 243-9		23
327	Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing. 2004 , 27, 145-72		82
326	Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. 2004 , 5, 895-931		195
325	Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. 2004 , 25, 193-200		488
324	Regulation of Xenobiotic Detoxification by PXR, CAR, GR, VDR and SHP Receptors: Consequences in Physiology. <i>Handbook of Experimental Pharmacology</i> , 2004 , 409-435	3.2	3
323	Quantitative structure-activity relationships (QSARs) for substrates of human cytochromes P450 CYP2 family enzymes. 2004 , 18, 89-97		24
322	Influence of azimilide on CYP2C19-mediated metabolism. 2004 , 44, 373-8		1
321	The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendations. 2004 , 1, 63-84		23
320	Maximum Recommended Doses of Local Anesthetics. 2004 , 29, 564-575		224
319	Gene activations of CYP2B1 and CYP3A1 by dihydropyridine calcium channel antagonists in the rat liver: the structure-activity relationship. 2004 , 27, 903-5		6
318	Effect of gamma-oryzanol on cytochrome P450 activities in human liver microsomes. 2004 , 27, 1151-3		5
317	Characterization of the CYP2C8 active site by homology modeling. 2004 , 52, 836-41		9

316	Characterization of the CYP3A4 active site by homology modeling. 2004 , 52, 830-5	26
315	Identification of human UDP-glucuronosyltransferase isoform(s) responsible for the glucuronidation of 2-(4-chlorophenyl)- 5-(2-furyl)-4-oxazoleacetic acid (TA-1801A). <i>Drug Metabolism and Pharmacokinetics</i> , 2005 , 20, 212-8	2.2 8
314	The effect of ketoconazole on the pharmacokinetics of a selective alpha 1A-adrenoceptor antagonist. 2005 , 45, 699-703	3
313	Effect of ciprofloxacin on the pharmacokinetics of intravenous lidocaine. 2005 , 22, 795-9	8
312	Drug-drug interactions in oncology: why are they important and can they be minimized?. 2005 , 55, 117-42	125
311	Acute drug prescribing to children on chronic antiepilepsy therapy and the potential for adverse drug interactions in primary care. 2005 , 59, 712-7	18
310	Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics. 2005 , 60, 486-93	42
309	Predicting in vivo drug interactions from in vitro drug discovery data. 2005 , 4, 825-33	664
308	Pharmacokinetics and metabolism of metoprolol and propranolol in the female DA and female Wistar rat: the female DA rat is not always an animal model for poor metabolizers of CYP2D6. 2005 , 94, 397-408	26
307	Alprazolam as a probe for CYP3A using a single blood sample: pharmacokinetics of parent drug, and of alpha- and 4-hydroxy metabolites in healthy subjects. 2005 , 61, 113-8	14
306	Identification of enzymes involved in phase I metabolism of ciclesonide by human liver microsomes. 2005 , 30, 275-86	22
305	Hydroxychalcones exhibit differential effects on XRE transactivation. 2005 , 207, 303-13	18
304	[Genetic polymorphism and drug interactions: their importance in the treatment of pain]. 2005 , 52, 806-21	23
303	Radical induction theory of ulcerative colitis. 2005 , 11, 2371-84	149
302	General principles of pharmacotherapy for the patient with HIV infection. 2005 , 56-87	
301	Measurement of hepatic functional mass by means of ¹³ C-methacetin and ¹³ C-phenylalanine breath tests in chronic liver disease: comparison with Child-Pugh score and serum bile acid levels. 2005 , 11, 142-8	47
300	Drug Interactions and Adverse Reactions. 2005 , 295-368	
299	Development and validation of a high-throughput radiometric CYP3A4/5 inhibition assay using tritiated testosterone. 2005 , 33, 349-58	24

298	Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. 2005 , 360, 1563-70		87
297	Development and validation of a high-throughput radiometric cyp2c9 inhibition assay using tritiated diclofenac. 2005 , 33, 359-64		15
296	Prediction of CYP2C9-mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes. 2005 , 33, 1700-7		48
295	Treatment of dyslipidaemia in HIV-infected persons. 2005 , 6, 1619-45		9
294	A novel polymorphic cytochrome P450 formed by splicing of CYP3A7 and the pseudogene CYP3AP1. 2005 , 280, 28324-31		20
293	Regioselective glucuronidation of denopamine: marked species differences and identification of human udp-glucuronosyltransferase isoform. 2005 , 33, 403-12		18
292	Characterization of afloqualone N-glucuronidation: species differences and identification of human UDP-glucuronosyltransferase isoform(s). 2005 , 33, 60-7		27
291	Chapter 12 Cytochrome p450 (cyp) and udp-glucuronosyltransferase (ugt) enzymes: role in drug metabolism, polymorphism, and identification of their involvement in drug metabolism. 2005 , 295-336		2
290	Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. 2005 , 14, 19-29		199
289	Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis. 2005 , 46, 565-8		19
288	In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. 2005 , 33, 1729-39		238
287	Structure-based methods for the prediction of the dominant P450 enzyme in human drug biotransformation: consideration of CYP3A4, CYP2C9, CYP2D6. 2005 , 16, 43-61		31
286	Prediction of oral clearance from in vitro metabolic data using recombinant CYPs: comparison among well-stirred, parallel-tube, distributed and dispersion models. <i>Xenobiotica</i> , 2005 , 35, 627-46	2	18
285	Usefulness of hepatocytes for evaluating the genetic polymorphism of CYP2D6 substrates. <i>Xenobiotica</i> , 2005 , 35, 575-87	2	5
284	A bioavailability score. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 3164-70	8.3	367
283	Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. 2005 , 338, 299-305		85
282	Catalytic turnover of pyrene by CYP3A4: evidence that cytochrome b5 directly induces positive cooperativity. 2005 , 438, 21-8		45
281	Interactions between antiretrovirals and antineoplastic drug therapy. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 111-45	6.2	76

280	Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 1067-81	6.2	107
279	Plasma clozapine concentration coefficients of variation in a long-term study. 2005 , 72, 131-5		45
278	Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5. <i>Xenobiotica</i> , 2006 , 36, 287-99	2	30
277	Drug interactions during therapy with three major groups of antimicrobial agents. 2006 , 7, 639-51		57
276	Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. 2006 , 29, 735-68		64
275	A mechanistic approach for the scaling of clearance in children. <i>Clinical Pharmacokinetics</i> , 2006 , 45, 683-704		161
274	Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population. 2006 , 7, 831-41		47
273	Possible drug-metabolism interactions of medicinal herbs with antiretroviral agents. 2006 , 38, 477-514		81
272	Genetic testing for pharmacogenetics and its clinical application in drug therapy. 2006 , 363, 177-86		33
271	In vitro interactions of water-soluble garlic components with human cytochromes p450. 2006 , 136, 806S-809S		24
270	[Drug interaction of fluvoxamine, a selective serotonin reuptake inhibitor]. 2006 , 128, 93-103		2
269	Therapeutic hypothermia-induced pharmacokinetic alterations on CYP2E1 chlorzoxazone-mediated metabolism in a cardiac arrest rat model. 2006 , 34, 785-91		73
268	Sedation in the mechanically ventilated patient. 2006 , 34, 2541-6		85
267	Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. 2006 , 61, 58-69		109
266	The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials. 2006 , 62, 512-26		93
265	Glucuronidation of DRF-6574, hydroxy metabolite of DRF-4367 (a novel COX-2 inhibitor) by pooled human liver, intestinal microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT1A1, 1A3 and 1A8. 2006 , 31, 299-309		3
264	Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. 2006 , 26, 1730-44		217
263	Antidepressant-drug interactions are potentially but rarely clinically significant. 2006 , 31, 1594-604; discussion 1614-5		27

262	Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. 2006 , 17, 2363-7	91
261	Crystal structure of human cytochrome P450 2D6. 2006 , 281, 7614-22	351
260	Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. 2006 , 34, 1291-300	94
259	Interaction of Herbal Constituents with Cytochrome P450 Enzymes. 2007 , 13, 239-247	5
258	Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. 2007 , 35, 1232-8	61
257	High-throughput radiometric CYP2C19 inhibition assay using tritiated (S)-mephenytoin. 2007 , 35, 1737-43	13
256	CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. 2007 , 35, 128-38	20
255	Polymorphic cytochrome P450 enzymes and post-marketing drug dosage revisions: clinical relevance to dermatologic therapies. 2007 , 26, 171-80	1
254	Involvement of glucocorticoid receptor and pregnane X receptor in the regulation of mouse CYP3A4 female-predominant expression by glucocorticoid hormone. 2007 , 35, 1880-5	10
253	Repeated Administration of d-Amphetamine Results in a Time-dependent and Dose-independent Sustained Increase in Urinary Excretion of p-Hydroxyamphetamine in Mice. 2007 , 53, 371-377	3
252	Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas. 2007 , 110, 3345-51	34
251	Effect of a nurse-implemented sedation protocol on the incidence of ventilator-associated pneumonia. 2007 , 35, 2031-6	213
250	Dextromethorphan as a potential neuroprotective agent with unique mechanisms of action. 2007 , 13, 272-93	58
249	Predicting the active doses in humans from animal studies: a novel approach in oncology. 2007 , 43, 1862-8	81
248	What common structural features and variations of mammalian P450s are known to date?. 2007 , 1770, 376-89	102
247	Ligand-based models for the isoform specificity of cytochrome P450 3A4, 2D6, and 2C9 substrates. 2007 , 47, 1688-701	81
246	Empirical regioselectivity models for human cytochromes P450 3A4, 2D6, and 2C9. <i>Journal of Medicinal Chemistry</i> , 2007 , 50, 3173-84	8.3 94
245	General Transition-State Force Field for Cytochrome P450 Hydroxylation. 2007 , 3, 1765-73	49

244	Direct differentiation of human embryonic stem cells to hepatocyte-like cells exhibiting functional activities. 2007 , 9, 51-62		139
243	Study on the cytochrome P450-mediated oxidative metabolism of the terpene alcohol linalool: Indication of biological epoxidation. <i>Xenobiotica</i> , 2007 , 37, 604-617	2	34
242	Modeling and Simulation of Pharmacokinetic Aspects of Cytochrome P450-Based Metabolic Drug-Drug Interactions. 2007 , 827-846		2
241	CYP1A1 and CYP2E1 polymorphism frequencies in a large Brazilian population. 2007 , 30, 1-5		3
240	Interactions métaboliques des antifongiques azolés. 2007 , 17, 168-176		4
239	Precolumn derivatization of cysteine residues for quantitative analysis of five major cytochrome P450 isoenzymes by liquid chromatography/tandem mass spectrometry. 2007 , 21, 3234-44		13
238	Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. 2007 , 32, 333-41		87
237	Review article: The prevalence and clinical relevance of cytochrome P450 polymorphisms. 2007 , 26 Suppl 2, 211-9		83
236	Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases. 2007 , 73, 1842-51		36
235	Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells. 2007 , 74, 496-503		85
234	The pivotal role of hepatocytes in drug discovery. 2007 , 168, 2-15		127
233	Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. 2007 , 116, 496-526		848
232	Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. 2007 , 63, 321-33		128
231	Generation of in-silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition QSAR models. 2007 , 21, 559-73		54
230	Analysis of CYP2D6 substrate interactions by computational methods. 2008 , 26, 947-56		39
229	Effects of ursodeoxycholic acid on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam in healthy volunteers. 2008 , 377, 629-36		14
228	Human embryonic stem cells: current technologies and emerging industrial applications. 2008 , 65, 54-80		76
227	Efficient differentiation of hepatocytes from human embryonic stem cells exhibiting markers recapitulating liver development in vivo. 2008 , 26, 894-902		335

226	Efficient differentiation of functional hepatocytes from human embryonic stem cells. 2008 , 26, 1117-27		336
225	Generation of a set of simple, interpretable ADMET rules of thumb. <i>Journal of Medicinal Chemistry</i> , 2008 , 51, 817-34	8.3	674
224	A comparative analysis of the transcriptome and signal pathways in hepatic differentiation of human adipose mesenchymal stem cells. 2008 , 275, 1260-73		49
223	Plasma concentrations of oral oxycodone are greatly increased in the elderly. 2008 , 84, 462-7		53
222	Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction. 2008 , 65, 680-92		80
221	Modulation of P450 enzymes by Cuban natural products rich in polyphenolic compounds in rat hepatocytes. 2008 , 172, 1-10		24
220	Potential of pharmacokinetic profiling for detecting herbal interactions with drugs. <i>Clinical Pharmacokinetics</i> , 2008 , 47, 383-97	6.2	30
219	Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. <i>Clinical Pharmacokinetics</i> , 2008 , 47, 743-52	6.2	117
218	Sulfoxide, Sulfur, and Nitrogen Oxidation and Dealkylation by Cytochrome P450. 2008 , 4, 1369-77		73
217	Part I: Liver function in oncology: biochemistry and beyond. 2008 , 9, 1092-101		97
216	Computational prediction of drug binding and rationalisation of selectivity towards cytochromes P450. 2008 , 4, 513-27		60
215	Human cytochromes P450 in the metabolism of drugs: new molecular models of enzyme-substrate interactions. 2008 , 4, 1181-6		23
214	Regulatory polymorphisms and their contribution to interindividual differences in the expression of enzymes influencing drug and toxicant disposition. 2008 , 40, 263-301		19
213	Cytochrome P450s: Drug-Drug Interactions. 2008 , 195-246		0
212	Integrated in vitro analysis for the in vivo prediction of cytochrome P450-mediated drug-drug interactions. 2008 , 36, 1126-34		34
211	Inflammation affects sufentanil consumption in ulcerative colitis. 2008 , 25, 188-92		2
210	Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19. 2008 , 18, 569-76		86
209	Cytochrome P450: Structure, Function, and Application in Drug Discovery and Development. 55-107		

208	Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 541-51	5.9	91
207	Cunninghamella--a microbial model for drug metabolism studies--a review. 2009 , 27, 16-29		166
206	Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption. 2009 , 98, 2180-97		39
205	[Drug interactions in geriatric medicine]. 2009 , 159, 462-9		4
204	Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance. 2009 , 26, 1073-83		93
203	Mini-series: I. Basic science. Uncertainty and inaccuracy of predicting CYP-mediated in vivo drug interactions in the ICU from in vitro models: focus on CYP3A4. 2009 , 35, 417-29		22
202	Novel therapeutic biosensor for indinavir-a protease inhibitor antiretroviral drug. 2009 , 49, 498-501		22
201	QSAR studies of CYP2D6 inhibitor aryloxypropanolamines using 2D and 3D descriptors. 2009 , 73, 442-55		66
200	Virtual screening and prediction of site of metabolism for cytochrome P450 1A2 ligands. 2009 , 49, 43-52		71
199	Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry. 2009 , 6, 1662-77		57
198	Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms. 2009 , 6, 1644-61		45
197	Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer. 2009 , 65, 345-50		46
196	Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity. 2009 , 12, 334-61		85
195	Predicting the clinical relevance of drug interactions from pre-approval studies. 2009 , 32, 1017-39		14
194	Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation. <i>Journal of Medicinal Chemistry</i> , 2009 , 52, 329-35	8.3	92
193	Dynamical spot queries to improve specificity in P450s based multi-drugs monitoring. 2009 ,		6
192	Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro. 2010 , 20, 677-86		57
191	The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects. 2010 , 4, 278-81		141

190	Theoretical considerations on quantitative prediction of drug-drug interactions. <i>Drug Metabolism and Pharmacokinetics</i> , 2010 , 25, 48-61	2.2	20
189	Mechanisms and Consequences of Drug-Drug Interactions. 2010 , 1		
188	In vitro interaction studies of diltiazem with H2 receptor antagonists. 2010 , 19, 698-716		1
187	Cytochrome P450 expression profile of the PICM-19H pig liver cell line: potential application to rapid liver toxicity assays. 2010 , 46, 11-9		8
186	Using a homology model of cytochrome P450 2D6 to predict substrate site of metabolism. 2010 , 24, 237-56		33
185	Pharmacogenetics of Cytochrome P450 Enzymes. 2010 , 421-432		1
184	Chlorzoxazone metabolism by porcine cytochrome P450 enzymes and the effect of cytochrome b5. 2010 , 38, 857-62		8
183	Statin therapy--Part II: Clinical considerations for cardiovascular disease. 2010 , 44, 421-33		16
182	Estimation of the interindividual variability of cytochrome 2D6 activity from urinary metabolic ratios in the literature. <i>Drug Metabolism and Pharmacokinetics</i> , 2010 , 25, 243-53	2.2	14
181	Structural features of cytochromes P450 and ligands that affect drug metabolism as revealed by X-ray crystallography and NMR. 2010 , 2, 1451-68		61
180	Prediction of Pharmacokinetics and Drug Safety in Humans. 2010 , 89-130		
179	Inhibition of human cytochromes P450 by components of Ginkgo biloba. 2004 , 56, 1039-44		114
178	The effects of cytochrome P450 induction by xenobiotics on endobiotic metabolism in pre-clinical safety studies. 2010 , 20, 159-66		35
177	Hepatic stem cells and liver development. 2010 , 640, 181-236		20
176	Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system. 2010 , 396, 90-4		52
175	Identification of genetic variants of human cytochrome P450 2D6 with impaired mitochondrial targeting. 2010 , 99, 90-7		34
174	Peptic Ulcer Disease. 2010 , 627-642		1
173	Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence. 2011 , 37, 1-11		28

172	Computational and Pharmacoinformatic Approaches to Oral Bioavailability Prediction. 2011 , 519-534	2
171	Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141). <i>Journal of Medicinal Chemistry</i> , 2011 , 54, 7860-83	8,3 27
170	Metabolism and biomarkers of heterocyclic aromatic amines in molecular epidemiology studies: lessons learned from aromatic amines. 2011 , 24, 1169-214	209
169	Thiomers: Inhibition of cytochrome P450 activity. 2011 , 78, 361-5	19
168	A systematic genetic polymorphism analysis of the CYP2C9 gene in four different geographical Han populations in mainland China. 2011 , 97, 277-81	25
167	Comparison of cytochrome P450 concentrations and metabolic activities in porcine hepatic microsomes prepared with two different methods. 2011 , 25, 343-6	45
166	Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. 1998 , 50, 997-1004	78
165	Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. 2011 , 90, 575-81	171
164	Strain Differences in the Induction of Cytochrome P450 3A1/3A2 and Nuclear Receptors in the Liver by Phenobarbital and Dexamethasone in Sprague-Dawley Rats and Dark Agouti Rats. 2011 , 57, 414-419	1
163	Prevalence of exposure to potential CYP450 pharmacokinetic drug-drug interactions among patients with chronic low back pain taking opioids. 2011 , 11, 230-9	42
162	Reactive oxygen species alter autocrine and paracrine signaling. 2011 , 51, 2041-7	16
161	Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients. 2011 , 67, 493-506	45
160	Sedation confounds outcome prediction in cardiac arrest survivors treated with hypothermia. 2011 , 15, 113-9	732
159	Databases in the area of pharmacogenetics. 2011 , 32, 526-31	38
158	Whole-cell biotransformation assay for investigation of the human drug metabolizing enzyme CYP3A7. 2011 , 1814, 161-7	17
157	Toxicological implications of modulation of gene expression by microRNAs. 2011 , 123, 1-14	66
156	Antidepressant treatment and altered CYP2D6 activity: are pharmacokinetic variations clinically relevant?. 2011 , 17, 330-9	30
155	Genetic polymorphism and toxicology--with emphasis on cytochrome p450. 2011 , 120, 1-13	185

154	Identification of six novel P450 oxidoreductase missense variants in Ashkenazi and Moroccan Jewish populations. 2012 , 13, 543-54		12
153	The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery. 2012 , 40, 1641-8		31
152	In vitro assessment of the allelic variants of cytochrome P450. <i>Drug Metabolism and Pharmacokinetics</i> , 2012 , 27, 68-84	2.2	83
151	Current and Future Tools for Predicting Clinical Drug-Drug Interactions. 2012 , 1		
150	Predicting Human Biotransformation Pathways. 2012 , 1		
149	Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to Microminipigs. 2012 , 37, 1157-64		28
148	The roles of different porcine cytochrome P450 enzymes and cytochrome b5A in skatole metabolism. 2012 , 6, 834-45		32
147	Comparison of Cytochrome P450 Mediated Metabolism of Three Central Nervous System Acting Drugs. 2012 , 60, 1544-1549		7
146	The impact of carbon-hydrogen bond dissociation energies on the prediction of the cytochrome P450 mediated major metabolic site of drug-like compounds. <i>European Journal of Medicinal Chemistry</i> , 2012 , 56, 48-55	6.8	28
145	Pharmacogenetics of pain and analgesia. 2012 , 82, 321-30		24
144	Allele and genotype frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese populations. 2012 , 16, 102-8		30
143	In Silico Models of Drug Metabolism and Drug Interactions. 2012 , 1		1
142	Impacts of low doses of pesticide mixtures on liver cell defence systems. 2012 , 26, 718-26		29
141	Optimization of the bacterial cytochrome P450 BM3 system for the production of human drug metabolites. 2012 , 13, 15901-24		76
140	Pharmacogenetics of P450 oxidoreductase: implications in drug metabolism and therapy. 2012 , 22, 812-9		28
139	CYP450 Enzymes in Drug Discovery and Development: An Overview. 2012 , 1		2
138	Gender issues. 2012 , 108, 759-81		4
137	Computational tools and resources for metabolism-related property predictions. 1. Overview of publicly available (free and commercial) databases and software. 2012 , 4, 1907-32		43

136	Sulfonamide Antibacterial Agents. 2012 , 103-126	5
135	Drug interactions--principles, examples and clinical consequences. 2012 , 109, 546-55; quiz 556	81
134	Genetics of Drug Disposition. 2012 , 1	
133	Pharmacological actions of statins: a critical appraisal in the management of cancer. 2012 , 64, 102-46	303
132	Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations. 2012 , 14, 94-101	24
131	Analysis of CYP2D6 genotype and response to tetrabenazine. 2013 , 28, 210-5	38
130	Suppressive effect of accumulated aluminum trichloride on the hepatic microsomal cytochrome P450 enzyme system in rats. 2013 , 51, 210-4	18
129	microRNAs as mediators of drug toxicity. 2013 , 53, 377-400	94
128	Update on allele nomenclature for human cytochromes P450 and the Human Cytochrome P450 Allele (CYP-allele) Nomenclature Database. 2013 , 987, 251-9	61
127	Chicken cytochrome P450 1A5 is the key enzyme for metabolizing T-2 toxin to 3OH-T-2. 2013 , 14, 10809-18	17
126	Pitavastatin Concentrations Are Not Increased by CYP3A4 Inhibitor Itraconazole in Healthy Subjects. 2013 , 2, 195-200	7
125	Growth and Development Symposium: Development, characterization, and use of a porcine epiblast-derived liver stem cell line: ARS-PICM-19. 2013 , 91, 66-77	11
124	Genetic polymorphisms of CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in Vietnamese-Koreans. 2014 , 22, 70	5
123	Antiretroviral medication: an emerging category of prescription drug misuse. 2014 , 23, 519-25	17
122	Use of physiologically based pharmacokinetic models coupled with pharmacodynamic models to assess the clinical relevance of current bioequivalence criteria for generic drug products containing Ibuprofen. 2014 , 103, 3263-75	30
121	A high-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry. 2014 , 28, 197-203	37
120	A High-Throughput (HTS) Assay for Enzyme Reaction Phenotyping in Human Recombinant P450 Enzymes Using LC-MS/MS. 2014 , 64, 9.18.1-10	1
119	Cellular impact of combinations of endosulfan, atrazine, and chlorpyrifos on human primary hepatocytes and HepaRG cells after short and chronic exposures. 2014 , 30, 17-29	28

118	Anti-epileptic drugs and hormonal treatments. 2014 , 16, 288		17
117	Effects of avermectin on microsomal cytochrome P450 enzymes in the liver and kidneys of pigeons. 2014 , 38, 562-9		8
116	A rapid and simple LC-MS/MS method for the simultaneous evaluation of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 hydroxylation capacity. 2014 , 6, 683-96		26
115	NMR-based metabonomic and quantitative real-time PCR in the profiling of metabolic changes in carbon tetrachloride-induced rat liver injury. 2014 , 89, 42-9		14
114	Medicinal Chemistry and Lead Optimization of Marine Natural Products. 2015 , 393-436		
113	eCounterscreening: using QSAR predictions to prioritize testing for off-target activities and setting the balance between benefit and risk. 2015 , 55, 231-8		12
112	Genetic variations in NADPH-CYP450 oxidoreductase in a Czech Slavic cohort. 2015 , 16, 205-15		4
111	Evolutionary History and Genetic Variation of <i>Macaca mulatta</i> and <i>Macaca fascicularis</i> . 2015 , 17-35		1
110	Effects of Ayurvedic Rasayana botanicals on CYP3A4 isoenzyme system. 2015 , 13, 165-72		4
109	Molecular docking of chemotherapeutic agents to CYP3A4 in non-small cell lung cancer. <i>Biomedicine and Pharmacotherapy</i> , 2015 , 73, 65-74	7.5	11
108	Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy. 2015 , 149, 1-123		221
107	A Workflow to Investigate Exposure and Pharmacokinetic Influences on High-Throughput in Vitro Chemical Screening Based on Adverse Outcome Pathways. 2016 , 124, 53-60		16
106	Emerging Roles for MicroRNAs in Perioperative Medicine. 2016 , 124, 489-506		46
105	Defining Known Drug Space Using DFT. 2016 , 35, 46-53		21
104	Cytochrome P450 Organization and Function Are Modulated by Endoplasmic Reticulum Phospholipid Heterogeneity. 2016 , 44, 1859-1866		32
103	MicroRNAs as key mediators of hepatic detoxification. 2016 , 368-369, 80-90		13
102	Metabolism-Based Drug-Drug Interactions in Critically Ill Patients: Clinical Relevance and Predictability of In Vitro Systems. 2016 , 1-48		
101	In vitro activity of <i>Lycium barbarum</i> (Goji) against major human phase I metabolism enzymes. 2016 , 13, 257-265		5

100	Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects. 2017 , 102, 688-700		291
99	Potential anticancer role of colchicine-based derivatives: an overview. 2017 , 28, 250-262		48
98	Risk Assessment via Metabolism and Cell Growth Inhibition in a HepG2/C3A Cell Line Upon Treatment with Arpadol and its Active Component Harpagoside. 2017 , 31, 387-394		6
97	Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy. 2017 , 27, 337-346		12
96	A non-destructive BFCOD assay for in vivo measurement of cytochrome P450 3A (CYP3A) enzyme activity in fish embryos and larvae. 2017 , 26, 809-819		7
95	3D engineered In vitro hepatospheroids for studying drug toxicity and metabolism. 2017 , 38, 8-18		13
94	Unbound liver concentration is the true inhibitor concentration that determines cytochrome P450-mediated drug-drug interactions in rat liver. <i>Xenobiotica</i> , 2017 , 47, 488-497	2	4
93	Oxidative Drug Metabolism by Mammalian Cytochrome P450 Enzymes Using Their Monooxygenase and Peroxygenase Functions. 2017 , 1-36		
92	ADME Optimization in Drug Discovery. 2017 , 34-44		1
91	Computational modeling of human oral bioavailability: what will be next?. 2018 , 13, 509-521		21
90	Common drug-drug interactions in antifungal treatments for superficial fungal infections. 2018 , 14, 387-398		13
89	Drugs for Tuberculosis. 2018 , 221-253		
88	Current knowledge of microRNA-mediated regulation of drug metabolism in humans. 2018 , 14, 493-504		31
87	New insights for risks of chlorophenols (CPs) exposure: Inhibition of UDP-glucuronosyltransferases (UGTs). 2018 , 206, 9-16		16
86	Ancestry-Adjusted Vitamin D Metabolite Concentrations in Association With Cytochrome P450 3A Polymorphisms. 2018 , 187, 754-766		1
85	ROLE OF CYTOCHROME P450S IN THE GENERATION AND METABOLISM OF REACTIVE OXYGEN SPECIES. 2018 , 7, 44-51		84
84	Effect of Korean Red Ginseng extracts on drug-drug interactions. 2018 , 42, 370-378		11
83	Quantitative prediction of the extent of drug-drug interaction using a physiologically based pharmacokinetic model that includes inhibition of drug metabolism determined in cryopreserved hepatocytes. <i>Xenobiotica</i> , 2018 , 48, 770-780	2	2

82	Exploring PTDH-P450BM3 Variants for the Synthesis of Drug Metabolites. 2018 , 19, 326-337		11
81	Application of Q2MM to predictions in stereoselective synthesis. 2018 , 54, 8294-8311		24
80	Effect of Drug Combination on Omeprazole Metabolism by Cytochrome P450 2C19 in Helicobacter pylori Eradication Therapy. 2019 , 67, 810-815		4
79	Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 2083-2098	8.3	47
78	Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance. <i>European Journal of Medicinal Chemistry</i> , 2019 , 179, 849-862	6.8	20
77	Generation of functional hepatocyte-like cells from human bone marrow mesenchymal stem cells by overexpression of transcription factor HNF4 α and FOXA2. 2019 , 18, 546-556		9
76	Exploring the Chemical Space of Cytochrome P450 Inhibitors Using Integrated Physicochemical Parameters, Drug Efficiency Metrics and Decision Tree Models. 2019 , 7, 26		3
75	Getting high with the most high: Entheogens in the Old Testament. 2019 , 3, 117-132		3
74	Understanding the relevance of herb-drug interaction studies with special focus on interplays: a prerequisite for integrative medicine. 2019 , 4, e15		30
73	Effect of an anxiolytic botanical containing <i>Souroubea sympetala</i> and <i>Platanus occidentalis</i> on in-vitro diazepam human cytochrome P450-mediated metabolism. 2019 , 71, 429-437		4
72	Mechanism-based inactivation of cytochrome P450 2D6 by chelidonine. 2019 , 33, e22251		3
71	Paracetamol-induced liver injury modelled in <i>Xenopus laevis</i> embryos. 2019 , 302, 83-91		9
70	Toward precision medicine in pediatric population using cytochrome P450 phenotyping approaches and physiologically based pharmacokinetic modeling. 2020 , 87, 441-449		5
69	ADME Prediction with KNIME: Development and Validation of a Publicly Available Workflow for the Prediction of Human Oral Bioavailability. 2020 , 60, 2660-2667		11
68	Impact of the Selective Orexin-1 Receptor Antagonist ACT-539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects. 2020 , 60, 931-941		3
67	Cloning and in vivo metabolizing activity study of CYP3A4 on amiodarone drug residues: A possible probiotic and therapeutic option. <i>Biomedicine and Pharmacotherapy</i> , 2020 , 127, 110128	7.5	
66	Plasma protein binding, metabolism, reaction phenotyping and toxicokinetic studies of fenarimol after oral and intravenous administration in rats. <i>Xenobiotica</i> , 2021 , 51, 72-81	2	1
65	Discovery and development of novel pyrimidine and pyrazolo/thieno-fused pyrimidine derivatives as potent and orally active inducible nitric oxide synthase dimerization inhibitor with efficacy for arthritis. <i>European Journal of Medicinal Chemistry</i> , 2021 , 213, 113174	6.8	2

64	A Perspective on Synthetic Biology in Drug Discovery and Development-Current Impact and Future Opportunities. <i>SLAS Discovery</i> , 2021 , 26, 581-603	3.4	5
63	Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues. <i>Annals of Translational Medicine</i> , 2021 , 9, 730	3.2	4
62	Identification of biomarkers to diagnose diseases and find adverse drug reactions by metabolomics. <i>Drug Metabolism and Pharmacokinetics</i> , 2021 , 37, 100373	2.2	11
61	Criterion for initiating hemodialysis based on serum caffeine concentration in treating severe caffeine poisoning. <i>American Journal of Emergency Medicine</i> , 2021 , 46, 70-73	2.9	2
60	Design and synthesis of novel aminoamides derivatives as Nav1.7 inhibitors for antinociception. <i>Chinese Chemical Letters</i> , 2021 ,	8.1	0
59	Translational control of enzyme scavenger expression with toxin-induced micro RNA switches. <i>Scientific Reports</i> , 2021 , 11, 2462	4.9	1
58	Characterization of Cytochrome P450 Mechanism-Based Inhibition. 1		2
57	Rational Design of P450 Enzymes for Biotechnology. <i>Focus on Biotechnology</i> , 2001 , 71-104		3
56	Dosisanpassung bei Leberinsuffizienz. 93-101		0
55	Mechanisms of Drug Interactions. 2001 , 13-38		3
54	Drugs for Tuberculosis. 2001 , 109-120		3
53	Antifungal Agents. 2001 , 185-217		5
52	Drugs for Tuberculosis. 2011 , 401-424		1
51	Mechanisms of Drug Interactions I: Absorption, Metabolism, and Excretion. 2011 , 11-41		1
50	Statins. 2015 , 123-147		1
49	Mechanisms of Drug Interactions I: Absorption, Metabolism, and Excretion. 2018 , 15-47		1
48	Molecular and Cellular Events Regulating Dopamine Neuron Survival. <i>Handbook of Experimental Pharmacology</i> , 2002 , 321-386	3.2	4
47	CHAPTER 1:How Physicochemical Properties of Drugs Affect Their Metabolism and Clearance. <i>RSC Drug Discovery Series</i> , 2015 , 1-26	0.6	7

46	Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. <i>Journal of Clinical Psychopharmacology</i> , 1999 , 19, 293-6	1.7	47
45	Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions. <i>Journal of Clinical Psychopharmacology</i> , 1999 , 19, 23S-35S	1.7	71
44	Human cytochromes mediating sertraline biotransformation: seeking attribution. <i>Journal of Clinical Psychopharmacology</i> , 1999 , 19, 489-93	1.7	23
43	Evaluation of analytical and clinical performance of a dual-probe phenotyping method for CYP2D6 polymorphism and CYP3A4 activity screening. <i>Therapeutic Drug Monitoring</i> , 2000 , 22, 486-96	3.2	17
42	Glucuronidation of 3-Azido-3-Deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid. <i>Antimicrobial Agents and Chemotherapy</i> , 1998 , 42, 1592-6	5.9	70
41	F429 Regulation of Tunnels in Cytochrome P450 2B4: A Top Down Study of Multiple Molecular Dynamics Simulations. <i>PLoS ONE</i> , 2015 , 10, e0137075	3.7	8
40	In-Silico Modeling in Drug Metabolism and Interaction: Current Strategies of Lead Discovery. <i>Current Pharmaceutical Design</i> , 2019 , 25, 3292-3305	3.3	5
39	The Simplest Flowchart Stating the Mechanisms for Organic Xenobiotics-induced Toxicity: Can it Possibly be Accepted as a "Central Dogma" for Toxic Mechanisms?. <i>Toxicological Research</i> , 2014 , 30, 179-84	3.7	9
38	Dosisanpassung bei Leberinsuffizienz. 2000 , 70-79		1
37	AIDS/HIV: Drugs for Opportunistic Infections. 2001 , 61-107		
36	Pharmacokinetics of Protease Inhibitors and Drug Interactions with Psychoactive Drugs. <i>AIDS Prevention and Mental Health</i> , 2002 , 33-60		
35	Pharmacology. 2002 , 13-35		
34	The Role of Pharmacokinetics in Drug Development. 2002 ,		
33	Clinical Evaluation of Drugs. 2002 , 127-138		
32	Development of neuroleptic agents: pharmacogenetics and current safety issues of regulatory concern. <i>Dialogues in Clinical Neuroscience</i> , 2002 , 4, 449-62	5.7	
31	Dosisanpassung bei Leberinsuffizienz. 2003 , 80-87		1
30	Drug-Drug Interactions. 2004 ,		
29	Scientific, Mechanistic and Regulatory Issues with Pharmacokinetic Drug-Drug Interactions. <i>Drugs and the Pharmaceutical Sciences</i> , 2004 , 297-343		

28	Le polymorphisme génétique des enzymes du métabolisme des médicaments. Une opportunité pour un traitement individualisé <i>Bulletin De L'Académie Nationale De Médecine</i> , 2006 , 190, 55-73	0.1	
27	Molecular Modelling Analysis of the Metabolism of Enrofloxacin. <i>Asian Journal of Biochemistry</i> , 2006 , 1, 316-324	0.1	1
26	DrugMetZ DB: an anthology of human drug metabolizing Cytochrome P450 enzymes. <i>Bioinformatics</i> , 2006 , 1, 248-50	1.1	
25	Hepatic Stem Cells and Liver Development. 2009 , 439-469		
24	Peptic Ulcer Disease. 2009 , 1122-1137		1
23	In Vitro Metabolism in Preclinical Drug Development. 1		
22	Utilization of In Vitro Cytochrome P450 Inhibition Data for Projecting Clinical Drug-Drug Interactions. 1		
21	Metabolite Profiling and Structural Identification. 1		0
20	Precision Dosing Management with Intelligent Computing in Digital Health. <i>Advances in Intelligent Systems and Computing</i> , 2021 , 269-280	0.4	
19	Clinically Relevant Interactions with Anti-Infectives on Intensive Care Units-A Multicenter Delphi Study. <i>Antibiotics</i> , 2021 , 10,	4.9	0
18	Identification of C5-NH Modified Oseltamivir Derivatives as Novel Influenza Neuraminidase Inhibitors with Highly Improved Antiviral Activities and Favorable Druggability. <i>Journal of Medicinal Chemistry</i> , 2021 ,	8.3	2
17	Interactions between the cytochrome P450 system and the second-generation antipsychotics. <i>Journal of Psychiatry and Neuroscience</i> , 2003 , 28, 99-112	4.5	92
16	Drug interactions and the statins. <i>Cmaj</i> , 1999 , 161, 1281-6	3.5	16
15	The influence of cytochrome P450 pharmacogenetics on disposition of common antidepressant and antipsychotic medications. <i>Clinical Biochemist Reviews</i> , 2006 , 27, 17-25	7.3	30
14	Effect of ademetionine on cytochrome P450 isoforms activity in rats. <i>International Journal of Clinical and Experimental Medicine</i> , 2015 , 8, 9716-22		
13	Inhibitory effect of salvianolate on human cytochrome P450 3A4 in vitro involving a noncompetitive manner. <i>International Journal of Clinical and Experimental Medicine</i> , 2015 , 8, 15549-55		6
12	Traditional Herbal Formulas to as Treatments for Musculoskeletal Disorders: Their Inhibitory Effects on the Activities of Human Microsomal Cytochrome P450s and UDP-glucuronosyltransferases. <i>Pharmacognosy Magazine</i> , 2016 , 12, 241-252	0.8	6
11	Pediatric Pharmacokinetic Data: Implications for Environmental Risk Assessment for Children. <i>Pediatrics</i> , 2004 , 113, 973-983	7.4	39

10	Oxazepam Detected in Urine 79 Days After Withdrawal of Diazepam: A Case Report.. <i>Journal of Addiction Medicine</i> , 2021 ,	3.8	
9	Cytochrome P450 enzymes and metabolism of drugs and neurotoxins within the mammalian brain. <i>Advances in Pharmacology</i> , 2022 ,	5.7	1
8	Simvastatin Does Not Affect CYP3A Activity, Quantified by the Erythromycin Breath Test and Oral Midazolam Pharmacokinetics, in Healthy Male Subjects. 2000 , 40, 1274-1279		2
7	Fate of drug-metabolizing enzymes in metabolic diseases. 2022 , 209-230		0
6	The Role of CYP3A in Health and Disease. 2022 , 10, 2686		1
5	PERSONALIZED STATIN THERAPY IN IMPROVING THE TREATMENT OF CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS. 2015 , 57-61		0
4	Characterization of Cytochrome P450 Mechanism Based Inhibition. 2022 , 465-526		0
3	Molecular Idiosyncratic Toxicology of Drugs in the Human Liver Compared with Animals: Basic Considerations. 2023 , 24, 6663		0
2	Pharmacogenomics in Asians: Differences and similarities with other human populations. 2023 , 19, 27-41		0
1	Simplifying the Extended Clearance Concept Classification System (EC3S) to Guide Clearance Prediction in Drug Discovery.		0